August 27, 2025 5:01pm

Which makes and mostly breaks August, so far

As I wrote this a.m., “Even as I see some aftermarket green, I expect more sentiment selling as we get closer to August’s month end and to the Labor Day holiday”

My insights are conveyed with a simplicity of language to highlight what is informative.

Never leave an investor uninformed!  

Looking for a break in the action (and computer) this week, the “bloodies with clam juice” will be out … earlier as the week-ends and holiday approaches!

As the leading voice of cell and gene therapy investors; it’s hard to be right so often, it’s about defining insight with hours, days, months and years of experience.

I answer or qualify the sector’s equity’s movement; with an emphasis on which company is gaining or losing stride in their portfolio for the short-term

 

Wednesday’s RegMed Investors’ (RMi) pre-open: What’s to fear, algo and electronic trading’s dread, the fear themselves! … https://www.regmedinvestors.com/articles/14080

RegMed Investors (RMi) Research Note: Harvard Apparatus GT (OTCQB): Just another wrinkle – Q2/25’s 10-Q – liabilities exceed cash position … https://www.regmedinvestors.com/articles/13812

 

Wednesday: The Dow closed UP +147.16 points or +0.32%, the S&P closed UP +15.46 points or +0.24% while the Nasdaq closed UP +45.87 points or +0.21%

  • Theme of the session, waiting for Nvidia (NVDA) earnings

Henry’omics: We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy

  •  Sentiment was kept in check as long-term Treasury yields continued to rise amid concerns around President Trump’s attempts to influence the Fed toward lower interest rates.

Tuesday’s advance/decline line opened positive with 18 incliners, 16 decliners and 1 flat ending with a negative close of 16 incliners, 17 decliners and 2 flats

Metrics:  Wednesday, the IBB was up +0.12%, the XBI was up +0.39% while the VIX was up +0.23 points or +1.57% at 14.85

 

Q3 – August – 10 negative and 9 positive closes

  • July – 1 market holiday, 13 positive and 9 negative closes

Q2/25: June – 1 market holiday, 1 neutral, 9 negative and 11 positive closes, May – 1 market holiday, 10 negative and 11 positive closes and April – 11 positive and 10 negative closes

 

Wednesday Closing UP (10 of 16) 

  • Alnylam Pharmaceuticals (ALNY +$2.98 after Tuesday’s +$7.56 after Monday’s -$10.74),
  • IQV Holdings (IQV +$1.04 after Tuesday’s -$0.26 after Monday’s -$3.21)
  • Supernus Therapeutics (SUPN +$0.75 after Tuesday’s -$0.11 after Monday’s -$0.45)
  • Ionis Pharmaceuticals (IONS +$0.58 after Tuesday’s +$0.35 after Monday’s -$0.87),
  • Ultragenyx Pharmaceuticals (RARE +$0.52 after Tuesday’s+$0.29 after Monday’s -$0.51),
  • Moderna (MRNA +$0.37 after Tuesday’s -$0.62 after Monday’s -$1.77),
  • Precigen (PGEN +$0.33 after Tuesday’s +$0.28),
  • Beam Therapeutics (BEAM +$0.22),
  • Generation Bio (GBIO +$0.22),
  • Compass Therapeutics (CMPX +$0.13),

Flat (2)

  • BioLife Solutions (BLFS)
  • Harvard Apparatus RT (OTCQB: HRGN)

Wednesday’s Closing DOWN (10 of 17): 

  • BioNTech SE (BNTX -$1.78 after Tuesday’s -$0.28 after Monday’s -$5.81),
  • CRISPR Therapeutics (CRSP -$1.35 after Tuesday’s +$0.75),
  • Lenz Therapeutics (LENZ -$1.27),
  • Vericel (VCEL -$0.56 after Tuesday’s +$0.66 after Monday’s -$1.24),
  • Regenxbio (RGNX -$0.30),
  • BioLife Solutions (BLFS -$0.22),
  • Prime Medicine (PRME -$0.20),
  • Sarepta Therapeutics (SRPT -$0.19),
  • Adverum Biotechnologies (ADVM -$0.12),
  • Agenus (AGEN -$0.09 after Tuesday’s +$0.24),

 

The BOTTOM LINE:  US stocks “inched” higher, today Wednesday as investors counted down to Nvidia's (NVDA) highly anticipated earnings report, seen as a pivotal test for the tech-driven summer rally.

  • Even after writing this a.m. Wednesday, “I am sick of hearing about Nvidia (NVDA) … as an indicator.  Regardless of whether you think about NVDA shares or not, its result will impact your portfolio in some way.’
  • However, “shares of NVDA account for roughly 8% of the S&P 500 and has the biggest weight in the benchmark according to FactSet data

Bond yields continued to push higher following President Trump's move to oust Fed governor Lisa Cook, which was marked by a relatively tame market reaction.

  • The Treasury yield curve also steepened to the highest level since April. The spread between the 2-year and 10-year yield now stands at 62 basis points

The Nasdaq inched higher which had been choppy earlier in the session after opening lower.

  • The Russell 2000 index of small-cap stocks was outperforming the major large-cap indexes, rising 0.7% and reaching near session highs.

For the week: so far …

  • The S&P 500 is up 14.49 points, or 0.2%.
  • The Dow is down 66.51 points, or 0.1%.
  • The Nasdaq is up 93.60 points, or 0.4%.
  • The Russell 2000 is up 11.85 points, or 0.5%.

As I wrote yesterday, Tuesday … “Despite the stock market's recent record highs, many investors are concerned that a downturn is on the horizon.”

  • Nearly 45% of U.S. investors admit to feeling "bearish" about the next 6 months, according to the most recent weekly survey from the American Association of Individual Investors, compared with 33% in late July. <The Street>

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • Yet, I was again on target … this 5:30 a.m.

Earnings: As earnings slowly come to the last few releases, collaborator revenues and runways has instilled share pricing with forward stability

  • Q2 results so far:  4 net incomes and 25 net losses of 29 releases to date

 

August: understand the “flow” …

  • 8/27 – Wednesday closed negative with 16 positive, 17 negative and 2 flats
  • 8/26 – Tuesday closed positive with 25 positive, 9 negative and 1 flat
  • 8/25 – Monday closed negative with 4 positive, 29 negative and 2 flats

Last week:

  • 8/22 – Friday closed positive with 30 positive, 4 negative and 1 flat
  • 8/21 - Thursday closed positive with 22 positive, 12 negative and 1 flat
  • 8/20 - Wednesday closed negative with 14 positive, 19 negative and 2 flats
  • 8/19 - Tuesday closed negative with 5 positive, 28 negative and 2 flats
  • 8/18 - Monday closed positive with 18 positive, 17 negative and 0 flat

 

“I hate to be so negative or contrarian but, this is a NO spin zone and truth is its product; I can always be WRONG but, I am mostly EARLY!”

  • If I have learned one thing as a former research analyst in a venture and public fund, operating executive, x-FBI, x-military officer and an adjunct (MBA) business school professor now a journalist; my life and your portfolio are largely tied to knowledge of price movements and questioning pricing targets and more.
  • I was once told by a “very” prominent figure early in my career, “write it right, keep it tight without hype and never lose the stride to guide the reader” – they were pretty simple instructions to follow!

 

Why do I keep repeating, so investors can make the connection …

The top three (3) performing in the session:   

  • Wednesday: Alnylam Pharmaceuticals (ALNY), IQVIA Holdings (IQV) and Supernus Therapeutics (SUPN)
  • Tuesday: Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN) and CRISPR Therapeutics (CRSP)
  • Monday: Intellia Therapeutics (NTLA), Adverum Biotechnologies (ADVM) and Harvard Apparatus RT (OTCQB: HRGN)
  • Friday: IQVIA Holdings (IQV), Vericel (VCEL) and Supernus Therapeutics (SUPN)

The worst three (3) in the session: 

  • Wednesday: BioNTech (BNTX), CRISPR Therapeutics (CRSP) and Lenz Therapeutics (LENZ)
  • Tuesday: Lenz Therapeutics (LENZ), Moderna (MRNA) and BioNTech (BNTX),
  • Monday: Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX) and IQVIA Holdings (IQV)
  • Friday: Alnylam Pharmaceuticals (ALNY), Ionis Pharmaceuticals IONS) and Agenus (AGEN)

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.